Latest
Recommended
Published: Sun, March 05, 2017
Medical | By Garry George

Analysts Estimates and Ratings: Juno Therapeutics Inc. (NASDAQ:JUNO)


Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute.

12/05/2016 - Juno Therapeutics, Inc. had its " rating reiterated by analysts at Maxim Group. Rockefeller Financial Services Inc. now owns 3,465 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 3,239 shares in the last quarter. Commerzbank Aktiengesellschaft FI acquired a new position in shares of Juno Therapeutics during the fourth quarter worth $192,000. An earnings estimate is an analyst's estimate for a company's future quarterly or annual earnings. NY increased its position in shares of Juno Therapeutics by 397.3% in the second quarter. State Street Corp now owns 1,658,792 shares of the biopharmaceutical company's stock valued at $63,764,000 after buying an additional 440,324 shares in the last quarter. Finally, Ellington Management Group LLC acquired a new position in shares of Juno Therapeutics during the fourth quarter worth $198,000. NY now owns 4,441 shares of the biopharmaceutical company's stock worth $171,000 after buying an additional 3,548 shares in the last quarter. Hedge funds and other institutional investors own 61.61% of the company's stock.

The share price of the company (NASDAQ:JUNO) was up +5.28%, with a high of 25.50 during the day and the volume of Juno Therapeutics, Inc. shares traded was 3987007. (JUNO) . Average true range (ATR-14) of the company is at 1.15. The share price of $22.62 is at a distance of 29.11 percent from its 52-week low and down -54.51 percent versus its peak.

The company's price sits 23.02% above from its 50-day moving average of $21.35 and -12.38% below from the stock's 200-day moving average which is $25.08. The total market capitalization remained at $2.52 billion.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 9th.

Earnings estimate: "4" Analysts are saying that the company to report next quarterly earnings of $-0.73 per share for period Quarter Ending_Jun-17. Juno Therapeutics had a negative net margin of 445.86% and a negative return on equity of 22.10%. However a year ago for the same quarter the company has reported $-0.78 EPS. For the current year the company's revenue estimates are $35.97M compared to high estimates of $75M according to the projection of 13 analysts. On average, equities analysts predict that Juno Therapeutics will post ($2.84) EPS for the current year.

A number of brokerages have issued reports on JUNO. BTIG Research raised shares of Juno Therapeutics from a sell rating to a neutral rating in a report on Thursday, November 3rd. Finally, Wedbush initiated coverage on shares of Juno Therapeutics in a report on Wednesday, February 1st. Zacks Investment Research lowered shares of Juno Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, January 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. The company presently has an average rating of Hold and a consensus target price of $37.45. Given that liquidity is king in short-term, JUNO is a stock with 109.23 million shares outstanding that normally trades 19.63% of its float.

Best time to invest in stock market is when things are on odd side, and it's not easy how to pick stocks.

Like this: